Cynergy treats all types of vascular lesions, including facial and leg telangiectasias, spider veins, hemangiomas, mature and blebbed port-wine stains, and rosacea

Cynergy device - image 002

Advanced Technology, Efficacious Outcomes

Cynergy treats vascular and pigmented lesions more effectively than conventional, single-wavelength platforms. With both a high-powered 585 nm pulsed-dye laser and a 1064 nm Nd:YAG laser, proprietary MultiPlex technology enables the sequential emission of two wavelengths from one delivery system for optimised clinical effectiveness.

Models used for illustrative purposes only. Individual results may vary and are not guaranteed.



What is Cynergy?

Cynergy is the first system to combine a long pulse pulse-dye-laser and a high powered Nd:YAG into one system. These wavelengths were chosen for their absorption characteristics and depth of penetration. Both wavelengths are well absorbed by blood.

Both wavelengths are also absorbed by melanin. The wavelengths are synergistic in their depth of penetration criteria, the PDL has a more shallow depth of penetration while the ND:YAG penetrates deeper.

What is Multiplex?

MultiPlex is the ability to sequentially fire different laser wavelengths through the same handpiece, with precise timing, to improve the outcome of treatment compared to single wavelength treatment. MultiPlex refers to Cynergy’s combination of PDL followed by YAG, with short, medium, long and extended delays between wavelengths.

Why is Multiplex better?

MultiPlex has been shown to provide 75% single-treatment clearance in 75% of subjects when treating facial telangiectasia, with little or no purpura. MultiPlex improves treatment of leg veins as well. MultiPlex has also been shown to improve outcomes for those with recalcitrant and resistant vascular birthmarks, and to allow treatment of lesions previously requiring surgery.

When should I choose Multiplex?

MultiPlex is the preferred method of treatment for discrete telangiectatic vessels from 0.2 to 1.2 mm in diameter, on the face and legs. It also provides additional treatment options for resistant or recalcitrant vascular birthmarks.

Why PDL first?

PDL energy is very well absorbed by blood (about 50x better than Nd:YAG), hence very little energy (typically less than 10 j/cm2) is required to heat blood sufficiently to cause conversion to Methemoglobin and/or thrombus (PDL products). Thus there is little background heating of tissue and less risk of thermal injury. Both Methemoglobin and thrombus provide favourable absorption characteristics for Nd:YAG (~3-5x better then normal blood), thus modest Nd:YAG fluence is required to provide effective treatment.

Because less Nd:YAG energy is used, there is a lower risk of side effects than Nd:YAG alone. The Nd:YAG absorption characteristics of Methemoglobin and thrombus are still much lower (~10x) than PDL, thus depth of penetration is not sacrificed.

If PDL only penetrates up to about 0.75-mm how does Multiplex allow deeper treatment?

General perfusion causes Methemoglobin and thrombus to flow deeper into the dermal tissue between the penetration depths of PDL & Nd:YAG wavelengths. This allows the Nd:YAG energy to interact at depth, with PDL exposure products that were created more superficially. Detailed studies have shown that even when a vessel appears to be clotted, there is typically some residual flow, allowing propagation of PDL products.

When to use short, medium, long, extended?

  • Short is required when treating discrete telangiectasia with high flow rates. This allows Nd:YAG to interact with PDL altered blood before it flows away from the treatment area.
  • Medium is used for treatment of large, moderate flow-rate vessels, and for treatment of resistant salmon-coloured Port Wine birthmarks.
  • Long and extended are use for treatment of other resistant vascular birthmarks. The longer delays allow altered blood to perfuse deeply into the lesions while providing time for epidermal cooling between wavelengths. This reduces the risk of epidermal injury when using MultiPlex for treatment of these lesions.

Do I need to use cooling with Multiplex

Yes, the PDL does introduce residual heat into the field of Nd:YAG treatment. Without efficient epidermal cooling, this can lead to epidermal injury.

The vessels disappeared, isn't a good thing?

Immediate vessel disappearance during laser treatment is a sign of vasospasm. Vasospasm occurs when a vessel is damaged, or irritated, but not necessarily destroyed. In the majority of cases, a vessel that displays vasospasm has been under treated, and will

return within days or weeks. Intravascular coagulation (darkening of the vessel itself, which cannot be blanched) is the preferred endpoint for treatment of telangiectasia, suggesting effective damage to the vessel wall. Intravascular coagulation generally

resolves within 1-3 weeks.

Clinical data

As a recognised industry leader, Cynosure’s Cynergy technology is strongly supported by clinical research.


Loading events ...

Your Practice & Cynosure

Keep your practice on top with the latest best-in-class offerings along with dedicated support and turnkey solutions when you partner with Cynosure.

Requestion Information (Contact Us)

  • This field is for validation purposes and should be left unchanged.
Cynergy device - image 002

Cynergy treats all types of vascular lesions, including facial and leg telangiectasias, spider veins, hemangiomas, mature and blebbed port-wine stains, and rosacea

Cynergy - Request Info

Cynosure is here to help your practice in any way we can. We have branch offices strategically located throughout Asia and Europe — and we maintain relationships with distributors across five continents. In the United States, our customer service representatives are available to physicians and practitioners 24 hours a day, 7 days a week.

  • This field is for validation purposes and should be left unchanged.